



Pharmacologic Agents for Treatment of Type 2 Diabetes

SCAN Formulary Drugs

| Medication | 2023 Formulary | | 2024 Formulary | | Dosing & Administration | Risk for Drug- Drug Interactions* | Adverse Drug Reactions |
|--|----------------|----|----------------|----|----------------------------------|-----------------------------------|--|
| | Tier | UM | Tier | UM | | | |
| Biguanides | | | | | | | |
| <i>metformin tabs</i> | 1 | | 1 | | 500 – 850 mg QD - TID | Neutral | Nausea/ vomiting, GI upset, metallic taste, diarrhea, flatulence, lactic acidosis (rare) |
| <i>metformin er uncoated tabs</i> 500 mg & 750 mg | 1 | | 1 | | 500 – 2000 mg daily | | Nausea/ vomiting, GI upset, diarrhea, flatulence, lactic acidosis |
| Sulfonylureas | | | | | | | |
| <i>glimepiride</i> | 1 | | 1 | | 1 – 8 mg daily | Moderate | Dizziness, headache, hypoglycemia, nausea, weight gain |
| <i>glipizide</i> | 1 | | 1 | | 2.5 – 20 mg daily | | Rash, diarrhea, dizziness, headache, diarrhea, hypoglycemia, nausea, weight gain |
| <i>glipizide er</i> | 1 | | 1 | | 5 – 20 mg daily | | Asthenia, headache, dizziness, rash, nausea, hypoglycemia, weight gain |
| <i>glipizide / metformin tabs</i> | 1 | | 1 | | 2.5 / 500 mg BID | Moderate | Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis |
| Thiazolidinediones & Thiazolidinedione Combination Agents | | | | | | | |
| <i>pioglitazone</i> | 1 | | 1 | | 15 – 45 mg daily | Neutral | Anemia, edema, weight gain, headache, myalgia, bone fracture, heart failure |
| <i>pioglitazone / metformin</i> | 2 | | 2 | | 15 / 500 mg – 45 / 1500 mg daily | | Rash, diarrhea, dizziness, headache, nausea, flatulence, hypoglycemia, lactic acidosis |
| <i>pioglitazone / glimepiride</i> | 2 | | 2 | | 15 / 500 mg – 45 / 2550 mg daily | | Anemia, edema, weight gain, headache, myalgia, dizziness, hypoglycemia, nausea |



| Alpha-Glucosidase Inhibitor | | | | | | | |
|---|---|--|---|--|---|----------|--|
| <i>acarbose</i> | 2 | | 2 | | 25 – 100 mg TID administered at the start of each meal to decrease postprandial glucose peaks | Neutral | Abdominal pain, diarrhea, flatulence, elevated serum transaminases |
| Meglitinides | | | | | | | |
| <i>nateglinide</i> | 2 | | 2 | | 60 – 120 mg TID before meals | Moderate | Dizziness, arthralgia, diarrhea, hypoglycemia, weight gain, increased uric acid |
| <i>repaglinide</i> | 2 | | 2 | | 0.5 – 4 mg TID before meals | | Hypoglycemia, arthralgia, diarrhea, weight gain |
| DPPis (Dipeptidyl Peptidase-4 Inhibitors) | | | | | | | |
| JANUMET, JANUMET XR (<i>sitagliptin / metformin</i>) | 3 | | 6 | | 100 / 2000 mg daily | Neutral | Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, flatulence, lactic acidosis, pancreatitis |
| JANUVIA (<i>sitagliptin</i>) | 3 | | 6 | | 100 mg daily | Neutral | Abdominal pain, diarrhea, headache, nasopharyngitis, nausea, URI, pancreatitis |
| JENTADUETO (<i>linagliptin / metformin</i>) | 3 | | 6 | | 2.5 / 1000 mg BID | Neutral | Nasopharyngitis hypoglycemia, cough, diarrhea |
| JENTADUETO XR (<i>linagliptin / metformin</i>) | 3 | | 6 | | 5 / 2000 mg daily | Neutral | Nasopharyngitis hypoglycemia, cough, diarrhea |
| TRADJENTA (<i>linagliptin</i>) | 3 | | 6 | | 5 mg daily | Neutral | Hypoglycemia, diarrhea, cough, nasopharyngitis, arthralgia |
| TRIJARDY XR (<i>empagliflozin / linagliptin / metformin</i>) | 3 | | 6 | | 25 / 5 / 2000 mg daily | Neutral | Upper respiratory tract infection, urinary tract infection, nasopharyngitis, diarrhea, constipation, headache, gastroenteritis |



| Insulins | | | | | | | |
|--|------|-----|------|-----|---------------------------------|---------|---|
| | Vial | Pen | Vial | Pen | | | |
| HUMALOG (<i>insulin lispro</i>) | 3 | 3 | 3 | 3 | Patient specific dosing applies | Neutral | Hypoglycemia, injection site reaction, lipodystrophy, hypokalemia |
| HUMALOG MIX 50/50, 75/25 (<i>insulin lispro / protamine</i>) | 3 | 3 | 3 | 3 | | | |
| HUMULIN 70/30 (<i>insulin human-regular / NPH</i>) | 3 | 3 | 3 | 3 | | | |
| HUMULIN N (<i>insulin NPH</i>) | 3 | 3 | 3 | 3 | | | |
| HUMULIN R (<i>insulin human-regular</i>) | 3 | - | 3 | - | | | |
| HUMULIN R U-500 (<i>insulin human-regular</i>) | 3 | 3 | 3 | 3 | | | |
| INSULIN GLARGINE | NF | NF | 3 | 3 | | | |
| INSULIN LISPRO | NF | - | 3 | - | | | |
| LANTUS (<i>insulin glargine</i>) | 3 | 3 | 3 | 3 | | | |
| LEVEMIR (<i>insulin detemir</i>) | NF | NF | 3 | 3 | | | |
| LYUMJEV (<i>insulin lispro</i>) | 3 | 3 | 3 | 3 | | | |
| TOUJEO / TOUJEO MAX (<i>insulin glargine</i>) | - | 3 | - | 3 | | | |
| TRESIBA (<i>insulin degludec</i>) | NF | NF | 3 | 3 | | | |



| GIP/GLP-1 Agonist (Glucose-dependent Insulinotropic Polypeptide / Glucagon-Like Peptide-1) | | | | | | | |
|---|---|---|---|---|---|---------|--|
| MOUNJARO (<i>tirzepatide</i>) | - | 3 | - | 3 | 5 mg to 15 mg SC weekly | Neutral | Diarrhea, nausea, vomiting, headache, abdominal pain, constipation |
| Insulin/GLP-1 Agonist Combination | | | | | | | |
| SOLIQUA (<i>insulin glargine / lixisenatide</i>) | - | 3 | - | 3 | 15 units to 60 units SC daily | Neutral | Hypoglycemia, diarrhea, nausea, vomiting, headache, pancreatitis |
| GLP-1 Agonist (Glucagon-Like-Peptide-1) | | | | | | | |
| BYDUREON (<i>exenatide er</i>) | 3 | | 3 | | 2 mg SC weekly | Neutral | Diarrhea, nausea, vomiting, constipation, headache, pancreatitis |
| BYETTA (<i>exenatide</i>) | 3 | | 3 | | 5 – 10 mcg SC BID | Neutral | |
| OZEMPIC (<i>semaglutide</i>) | 3 | | 3 | | 0.5 – 1 mg weekly | Neutral | Diarrhea, nausea, vomiting, constipation, headache, pancreatitis |
| RYBELSUS (<i>semaglutide</i>) | 3 | | 3 | | 0.5 – 1 mg weekly | Neutral | Diarrhea, nausea, vomiting, constipation, headache, pancreatitis |
| TRULICITY (<i>dulaglutide</i>) | 3 | | 3 | | 0.75 – 1.5 mg weekly | Neutral | Diarrhea, nausea, vomiting, constipation, headache, pancreatitis |
| VICTOZA (<i>liraglutide</i>) | 3 | | 3 | | 0.6 mg – 1.8mg SC daily | Neutral | Diarrhea, nausea, vomiting, constipation, headache, pancreatitis |
| Amylinomimetic | | | | | | | |
| SYMLIN PEN (<i>pramlintide</i>) | 5 | | 5 | | 60 mcg – 120 mcg SC prior to main meals | Neutral | Nausea, anorexia, dizziness, fatigue |
| SGLT2 Inhibitor (Sodium-Glucose Cotransporter 2) | | | | | | | |
| FARXIGA (<i>dapagliflozin</i>) | 3 | | 6 | | 5 – 10 mg daily | Neutral | Genital mycotic infections, nasopharyngitis, UTI, back pain, increased urination, nausea |
| GLYXAMBI (<i>empagliflozin / linagliptin</i>) | 3 | | 6 | | 10 / 5 – 25 / 5 mg daily | Neutral | Urinary tract infections, nasopharyngitis, hypoglycemia, cough, diarrhea, upper respiratory tract infections |
| JARDIANCE (<i>empagliflozin</i>) | 3 | | 6 | | 10 – 25 mg daily | Neutral | Urinary tract infections and female genital mycotic infections |



| | | | | | | | |
|---|---|--|---|--|---------------------------------|---------|---|
| SYNJARDY (<i>empagliflozin / metformin</i>) | 3 | | 6 | | 12.5 / 1000 mg BID | Neutral | Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache |
| SYNJARDY XR (<i>empagliflozin / metformin</i>) | 3 | | 6 | | 25 / 2000 mg daily | Neutral | Urinary tract infections, female genital mycotic infections, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache |
| XIGDUO XR (<i>dapagliflozin / metformin</i>) | 3 | | 6 | | 5 / 500 – 10 / 2000 mg daily | Neutral | Low vitamin-B12, diarrhea, headache, UTI, genital mycotic infection, nasopharyngitis |
| Mineralcorticoid Receptor Antagonist | | | | | | | |
| KERENDIA (<i>finerenone</i>) | 3 | | 3 | | 20 mg daily | Neutral | Hypotension, hyponatremia, hyperkalemia |

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[NF] = Non-formulary

* 2019 AACE/ACE Consensus Statement



Diabetes Guidelines References

SCAN Health Plan Diabetes Guidelines adapted from:

- American Diabetes Association; Standards of Medical Care in Diabetes-2022: Diabetes Care January 2022 vol. 45 no. Supplement 1 S1-S2 (Accessed 9/6/2022)
- Summary of Revisions: Standards of Medical Care in Diabetes 2022. Diabetes Care 2022;45(Suppl. 1):S4–S7 | <https://doi.org/10.2337/dc22-SREV>
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. Endocrine Practice. (2020, January). Vol. 26, No. 1, pp. 107-139.
- Drug Facts & Comparisons. (2023, Sept). Retrieved from www.online.factsandcomparisons.com. Wolters Kluwer Health: Deventer, The Netherlands.
- Epocrates Online (2023, Sept). Retrieved from: <http://online.epocrates.com>. Epocrates, Inc.: San Mateo, California.
- Reuben, D. B., Herr, K. A., Pacala, J. T., Pollock, B. G., Potter, J. F., & Semla, T. P. (2015). Geriatrics at your fingertips. 17th ed. (Based on AGS Guidelines.)
- Online Lexicomp (09/2023): 1100 Terex Road, Hudson, OH 44236